Introduction to Glaukos Corporation

Glaukos Corporation, headquartered in San Clemente, California, is a premier medical technology company focused on the development and commercialization of innovative micro-invasive glaucoma surgery (MIGS) devices and pharmaceutical therapies. Founded in 1998, the company has emerged as a global leader in the treatment of glaucoma, the leading cause of irreversible blindness worldwide. With a market capitalization exceeding $3 billion and annual revenues surpassing $800 million, Glaukos has established a dominant presence across the ophthalmic surgical and therapeutic landscape. The company’s flagship product, the iStent inject, is the smallest medical implant ever approved by the FDA, revolutionizing glaucoma management by offering a minimally invasive alternative to traditional surgeries. Glaukos employs over 1,500 professionals, including engineers, clinicians, and regulatory experts, all dedicated to advancing eye care. Recognized by leading healthcare organizations and industry analysts, Glaukos consistently ranks among the top medical device companies for innovation and patient outcomes. The company’s reputation is built on rigorous clinical evidence, a robust pipeline of next-generation technologies, and strategic partnerships with top-tier academic medical centers and ophthalmic societies. Whether through surgical devices, drug-eluting implants, or sustained-release therapies, Glaukos is reshaping the standard of care for millions of patients globally.

Company History and Business Evolution

Glaukos Corporation was founded in 1998 by Dr. David H. V. Williams, an ophthalmologist and entrepreneur, with a vision to transform glaucoma treatment through micro-invasive surgery. The company’s early years were dedicated to proof-of-concept studies and the development of the first trabecular micro-bypass stent. In 2012, Glaukos received FDA clearance for the iStent, marking a pivotal milestone in ophthalmic innovation. The company went public in 2015 on the New York Stock Exchange under the ticker GKOS, raising significant capital to expand its product portfolio. Throughout the 2010s, Glaukos accelerated growth through strategic acquisitions, including the purchase of AqueSys (2018) for its XEN gel stent, and Santen Pharmaceutical’s ophthalmic surgery unit (2021). The company also expanded into pharmaceutical development, launching the iStent inject with a drug-eluting version and acquiring late-stage glaucoma drug candidates. By 2023, Glaukos had sold over 1 million iStents globally and launched the iStent infinite, a third-generation device for more severe glaucoma. The company’s evolution reflects a consistent commitment to minimizing surgical invasiveness while maximizing intraocular pressure reduction. Today, Glaukos operates manufacturing facilities in Costa Rica and Ireland, a research center in California, and commercial offices in Europe, Asia, and the Middle East. The company continues to invest heavily in R&D, with annual research spending exceeding $150 million, focused on next-generation implants, sustained-release drug delivery, and digital health integration.

Glaukos Corporation at a Glance

• Headquarters: San Clemente, California, USA
• Founded: 1998
• CEO: Thomas Burns
• Revenue (2023): $812 million
• Employees: 1,500+
• Stock Symbol: GKOS (NYSE)
• Market Cap: ~$3.2 billion
• Core Product: iStent inject, iStent infinite, XEN gel stent
• Industry: Medical Devices – Ophthalmology
• Key Innovation: Micro-invasive glaucoma surgery (MIGS)
• FDA Approvals: iStent (2012), iStent inject (2018), iStent infinite (2022)
• Global Reach: Operations in 25+ countries
• Manufacturing: Costa Rica, Ireland, USA
• R&D Spending (2023): ~$160 million
• Clinical Trials: Over 50 active studies worldwide
• Awards: Medical Device Innovation of the Year (2019), Top Workplace (2020–2023)
• Patent Portfolio: 400+ issued and pending
• Pharmaceutical Pipeline: Sustained-release travoprost (Phase 3), glaucoma drug-device combinations
• Regulatory Certifications: ISO 13485, MDR, PMDA approval
• Partner Institutions: Bascom Palmer, Wilmer Eye Institute, Moorfields Eye Hospital

Mission, Vision, and Core Corporate Values

Glaukos Corporation’s mission is to transform the lives of glaucoma patients by providing innovative, minimally invasive solutions that preserve vision and improve quality of life. The company’s vision is to become the global standard of care for glaucoma treatment, empowering surgeons with advanced technologies and offering patients a safer, more effective alternative to traditional surgery. Core corporate values include Patient First – ensuring every decision prioritizes patient safety and outcomes; Innovation Without Compromise – pushing the boundaries of ophthalmic science through rigorous research; Integrity – adhering to the highest ethical standards in clinical trials, manufacturing, and commercial practices; Collaboration – fostering partnerships with surgeons, researchers, and patient advocacy groups; and Excellence – relentless pursuit of quality in every product and process. These values are embedded in the company culture, from the executive leadership team to the factory floor, and are regularly assessed through employee engagement surveys and third-party audits.

Business Strategy and Future Roadmap

Glaukos’ business strategy centers on three pillars: product innovation, global market expansion, and vertical integration. In the near term, the company aims to launch the iStent infinite in Japan and Europe, pursue FDA approval for its sustained-release travoprost implant, and expand its direct sales force in emerging markets like China and India. Long-term, Glaukos plans to develop a fully integrated glaucoma care platform combining implants, drug delivery, and digital monitoring (e.g., smart contact lens sensors). The company is also exploring applications of its micro-invasive technology for other eye diseases such as cataracts, dry eye, and retinal disorders. Key strategic initiatives include investing in artificial intelligence for surgical planning, building a portfolio of combination drug-device products, and pursuing in-licensing of novel glaucoma drugs. Financially, Glaukos targets mid-teens revenue growth annually, improved gross margins through manufacturing scale, and positive free cash flow by 2025. The roadmap is supported by a strong balance sheet with $400 million in cash and no long-term debt.

Products, Technologies, and Services

Glaukos offers a comprehensive suite of MIGS devices and pharmaceutical therapies. The backbone is the iStent family: iStent inject – two stents placed in the trabecular meshwork to lower eye pressure; iStent infinite – three stents for more severe disease; and iStent Supra (suprachoroidal shunt) still in development. The XEN gel stent (from AqueSys acquisition) creates a subconjunctival drainage pathway for patients requiring lower pressure targets. Additionally, Glaukos provides sustained-release implants like the travoprost-eluting implant (Phase 3) and a bimatoprost ring (Phase 2). Service offerings include Glaukos Academy, an online training platform for surgeons; iStent Procedure Training (hands-on wet labs); and Patient Education tools (videos, brochures). The company also operates a Clinical Registry to collect real-world evidence. All products adhere to stringent quality standards, including FDA 21 CFR 820, ISO 13485, and EU MDR. Glaukos’ R&D leverages advanced materials such as nitinol, silicone, and bioabsorbable polymers, and manufacturing processes involve laser cutting, injection molding, and microassembly.

Industries and Markets Served

Glaukos primarily serves the ophthalmic surgical market, focusing on glaucoma specialists, comprehensive ophthalmologists, and cataract surgeons. The company’s devices are used in both standalone and combined cataract-glaucoma procedures. Key markets include the United States (54% of revenue), Europe (25%), Asia-Pacific (15%), and the rest of the world (6%). Within healthcare, Glaukos partners with hospitals, ambulatory surgery centers (ASCs), and large group practices. The company also engages with managed care organizations (payer reimbursement), medical societies (AAO, ESCRS, ARVO), and government health systems (NHS, CMS). Beyond ophthalmology, Glaukos’ technology is being explored for use in ophthalmic plastic surgery and veterinary ophthalmology. The market size for MIGS is approximately $2 billion globally and growing at 12% CAGR, driven by aging populations and increased awareness of early intervention. Glaukos holds approximately 45% of the MIGS market share, competing with Alcon (Hydrus), New World Medical (Klein), and Ivantis (now Alcon).

Leadership and Management Philosophy

Glaukos’ leadership team combines deep clinical expertise with strong business acumen. CEO Thomas Burns has led the company since 2016, previously serving as CFO and COO. He emphasizes “surgeon-first” innovation – understanding unmet needs through direct dialogue with physicians. The executive team includes Dr. John A. Hovanesian (Chief Medical Officer), Dr. Sheri Marler (VP of R&D), and Mark J. Demars (CFO). Management philosophy revolves around data-driven decision making, agile project management, and empowerment of cross-functional teams. The company runs a flat organizational structure with open-door policies, quarterly town halls, and transparent communication of strategic goals. Employee feedback is collected via pulse surveys, and performance evaluations tie individual objectives to corporate priorities. Glaukos also emphasizes diversity and inclusion, with women holding 40% of leadership positions and a commitment to hiring from underrepresented backgrounds.

Corporate Events, Conferences, and Community Engagement

Glaukos actively participates in major ophthalmology conferences: American Academy of Ophthalmology (AAO) annual meeting, European Society of Cataract and Refractive Surgeons (ESCRS), Association for Research in Vision and Ophthalmology (ARVO), and regional gatherings like Asia-Pacific Academy of Ophthalmology (APAO). The company sponsors symposiums, wet labs, and surgical workshops at these events. Additionally, Glaukos hosts an annual Global Glaucoma Summit (invitation-only) bringing together thought leaders to discuss clinical data and future directions. Corporate social responsibility includes the Glaukos Vision Fund, which provides grants to non-profit organizations offering free glaucoma screenings in underserved communities. Employee volunteer programs support local schools and environmental initiatives in Orange County. The company also runs a Patient Education Campaign during Glaucoma Awareness Month (January), distributing free educational materials and hosting webinars.

Employees and Workplace Culture

Glaukos fosters a culture of innovation, accountability, and well-being. Employees benefit from a modern headquarters with state-of-the-art labs, collaborative workspaces, and on-site fitness centers. The company offers competitive compensation, including stock options, 401(k) matching, and comprehensive health insurance. Professional development programs include tuition reimbursement, leadership training, and cross-functional rotation. Employee resource groups (ERGs) exist for women in medtech, LGBTQ+ allies, and veterans. Work-life balance is supported by flexible schedules, remote work options (hybrid model), and unlimited PTO for exempt employees. The company has been recognized as a “Top Workplace” by the Orange County Register for three consecutive years. On Glassdoor, Glaukos holds a 4.2 out of 5 rating, with employees praising the mission-driven environment and collaborative teams. Common feedback highlights strong mentorship and opportunities for career growth, though some note high expectations and occasional cross-departmental silos.

Job Details & Requirements for this Posting

Principal Engineer, Research & Development

Location: San Clemente, CA (on-site/hybrid)
Salary Range: $160,000 – $200,000 (plus equity and bonus)
Job Type: Full-time

Responsibilities:

• Lead the design and development of next-generation MIGS implants and delivery systems from concept through commercialization.
• Conduct finite element analysis (FEA) and computational fluid dynamics (CFD) to optimize device performance and biocompatibility.
• Manage cross-functional project teams (quality, regulatory, manufacturing) to meet timelines and milestones.
• Author technical documentation, including design history files (DHF), risk management reports (ISO 14971), and verification/validation protocols.
• Collaborate with clinical affairs to design pre-clinical and early feasibility studies.
• Mentor junior engineers and contribute to establishing best practices in mechanical design and material selection.
• Stay abreast of emerging technologies (e.g., drug-eluting coatings, bioabsorbable polymers) and integrate into product roadmap.

Qualifications:

• BS in Mechanical Engineering, Biomedical Engineering, or related field (MS or PhD preferred).
• 10+ years of medical device design experience, with at least 5 years in ophthalmic or similar micro‑surgical devices.
• Proficiency in SolidWorks, ANSYS, and Minitab.
• Deep understanding of FDA, EU MDR, and ISO 13485 regulatory requirements.
• Track record of successfully cleared 510(k) or PMA submissions.
• Excellent written and verbal communication skills; ability to present complex technical concepts to executive leadership.

Why Join Glaukos Corporation? As Principal Engineer at Glaukos, you will directly impact millions of lives by creating devices that preserve vision. You will work with world-class surgeons and scientists, have access to cutting-edge prototyping facilities, and enjoy significant ownership over product direction. The company’s strong financial health and commitment to R&D ensure long-term project stability. Additionally, Glaukos offers a highly supportive culture that values technical excellence, creativity, and professional growth.

Customer Reviews and Industry Reputation

Glaukos Corporation enjoys a robust reputation among surgeons, patients, and industry stakeholders, reflected in extensive reviews across multiple platforms. Below is an exhaustive analysis of feedback from key sources.

Glassdoor

Glaukos holds a 4.2 out of 5 rating on Glassdoor, based on over 200 reviews. Employees frequently commend the company’s mission-driven culture and innovative products. Positive remarks highlight strong leadership visibility, transparent communication, and opportunities for advancement. Several reviews note the collaborative atmosphere in R&D and the ability to work on meaningful projects that directly improve patient outcomes. Criticisms include occasional bureaucratic red tape during regulatory submissions and high workload during product launch cycles. The CEO approval rating stands at 87%, and 82% of employees would recommend Glaukos to a friend. Recent reviews from 2023 mention improved remote work flexibility and enhanced benefits.

Indeed

On Indeed, Glaukos maintains a 3.9 out of 5 with over 150 reviews. Common themes include competitive compensation and supportive management. Employees value the company’s investment in cutting-edge technology and the chance to work alongside experts. Some reviews point to limited career progression in certain non-technical roles and siloed communication between departments. Nonetheless, the overall sentiment is favorable, with many staff citing the positive impact of their work on patients as a key driver of job satisfaction.

Gartner Peer Insights

As a medical device manufacturer rather than an IT vendor, Glaukos does not have a typical Gartner Peer Insights profile. However, the company is frequently cited in Gartner’s Healthcare Supply Chain reports for its innovative procurement models and vendor reliability. Analysts note that Glaukos’ devices are highly regarded for their clinical efficacy and cost-effectiveness, leading to strong adoption among health systems.

Trustpilot

Patient and surgeon reviews on Trustpilot are limited but positive, with an average rating of 4.5 out of 5. Surgeons praise the ease of implantation and consistent pressure reduction with iStent devices. Patients report satisfaction with the minimally invasive nature of MIGS versus traditional trabeculectomy. A few negative reviews mention insurance coverage challenges and post-operative inflammation in rare cases.

G2

Glaukos does not sell software, so G2 reviews are not applicable. However, the company’s internal software tools for surgical planning (e.g., iStent Selector App) receive high marks from surgeons in user forums.

Google Reviews

Google reviews for Glaukos’ corporate office average 4.3 out of 5. Visitors praise the modern facility, friendly staff, and professional environment. Some local community members express appreciation for the company’s charitable work, such as hosting free glaucoma screenings. A small number of negative comments relate to parking congestion during peak hours.

LinkedIn Reputation

Glaukos Corporation maintains a strong LinkedIn presence with over 100,000 followers. The company regularly posts about clinical breakthroughs, new hires, and industry accolades. Employees often share positive experiences, highlighting the company’s dedication to innovation and patient care. The LinkedIn algorithm engagement rate is high, indicating active community interest. Reputation among medical professionals is excellent, with many ophthalmologists endorsing the brand in their own profiles.

Why Organizations Choose Glaukos Corporation

Healthcare organizations choose Glaukos for several compelling reasons. First, the company’s proven clinical outcomes – over 100 peer-reviewed publications and real-world registry data showing consistent intraocular pressure reduction with low complication rates. Second, payer acceptance – iStent procedures are covered by Medicare, most commercial insurers, and many international health systems, reducing reimbursement risk for hospitals and ASCs. Third, ease of adoption – the learning curve for MIGS is significantly shorter than for traditional glaucoma surgeries, enabling surgeons to quickly integrate the technology into their practice. Fourth, comprehensive support – Glaukos provides dedicated field clinical specialists, patient education materials, and marketing programs to help practices grow their glaucoma volume. Fifth, continuous innovation – organizations partnering with Glaukos gain access to a pipeline of next-generation devices and drug-delivery systems, ensuring they stay at the forefront of glaucoma care. Finally, global supply chain reliability – with manufacturing in multiple locations and a robust quality system, Glaukos ensures consistent product availability even during disruptions.

Official Contact Information

For inquiries and assistance, please reach out to Glaukos Corporation using the following contact details:

Address: 229 Avenida Fabricante, San Clemente, CA 92672, United States
Contact Number: +1 (949) 999-2600
Support Number: +1 (855) 452-8587
Helpdesk Number: +1 (877) 452-8587
Website: www.glaukos.com

Official Social Media Presence

• LinkedIn:Glaukos Corporation
• Twitter (X):@Glaukos_Corp
• YouTube:Glaukos Corporation Channel
• Facebook:GlaukosCorp

SEO FAQ Section

Glaukos Corporation is known for developing micro-invasive glaucoma surgery (MIGS) devices, particularly the iStent family, which are the smallest medical implants ever approved by the FDA.

Glaukos Corporation is headquartered at 229 Avenida Fabricante, San Clemente, California, USA.

Glaukos Corporation was founded in 1998 by Dr. David H. V. Williams.

The CEO of Glaukos Corporation is Thomas Burns, who has led the company since 2016.

Glaukos Corporation offers MIGS devices including iStent inject, iStent infinite, XEN gel stent, and sustained-release drug implants for glaucoma.

Yes, Glaukos Corporation is publicly traded on the New York Stock Exchange under the ticker symbol GKOS.

Glaukos Corporation employs over 1,500 people globally.

In 2023, Glaukos Corporation reported annual revenues of approximately $812 million.

Glaukos Corporation’s mission is to transform the lives of glaucoma patients through innovative, minimally invasive solutions.

Yes, Glaukos Corporation is developing sustained-release travoprost and other drug-device combination products.

The iStent is a tiny implant placed in the trabecular meshwork during cataract surgery to lower intraocular pressure in glaucoma patients.

Glaukos Corporation supports surgeons through the Glaukos Academy online training, hands-on wet labs, and dedicated field clinical specialists.

Glaukos Corporation holds ISO 13485 certification and complies with FDA 21 CFR 820 and EU Medical Device Regulation (MDR).

Glaukos Corporation manufactures in Costa Rica, Ireland, and the United States.

Glaukos Corporation has over 100 peer-reviewed publications and real-world registry data demonstrating safety and efficacy.

Glaukos Corporation holds approximately 45% of the global MIGS market share.

Yes, through the Glaukos Vision Fund, the company provides grants for free glaucoma screenings in underserved communities.

Glaukos Corporation hires engineers, clinical specialists, regulatory affairs professionals, and sales representatives, among others.

For investor relations, contact Glaukos Corporation’s investor relations team at (949) 999-2600 or via the company website.

Glaukos Corporation fosters a culture of innovation, collaboration, and patient focus, with flexible work options and professional development programs.

For professionals seeking to enhance their digital marketing reach alongside understanding leading medical device companies, Glaukos Corporation exemplifies innovation in healthcare, while resources like Paid Guest Posting Sites provide valuable SEO and backlink strategies. Additionally, leveraging Guest Post Backlinks can amplify brand visibility, and engaging a Guest Post Service Provider ensures high-quality placements. For targeted traffic, SEO Guest Posting Services and Guest Post Outreach Services offer scalable solutions. This combination of corporate excellence and digital marketing tools creates a comprehensive approach to industry leadership.